Shareholders Approve Doubling Authorized Stock to 240M Shares, Enabling Significant Future Dilution

summarizeSummary

Spero Therapeutics shareholders approved a charter amendment to double authorized common stock to 240 million shares and a new stock incentive plan reserving 12.9 million shares.

check_boxKey Events

• Authorized Shares Doubled

  Shareholders approved an amendment to increase the total number of authorized common stock from 120,000,000 to 240,000,000 shares. With 57,901,493 shares outstanding, this creates potential for over 300% dilution if all authorized shares were issued.

• New Stock Incentive Plan Approved

  The 2026 Stock Incentive Plan was approved, authorizing the issuance of up to 12,895,866 shares of common stock for compensation, representing approximately 22% of current outstanding shares.

• Annual Meeting Results

  The company re-elected two Class III directors, ratified PricewaterhouseCoopers LLP as its independent auditor, and approved the advisory vote on executive compensation.

auto_awesomeAnalysis

Spero Therapeutics' shareholders approved a substantial increase in authorized common stock, doubling it from 120 million to 240 million shares. This move, while not an immediate issuance, provides the company with significant headroom to raise capital or fund strategic initiatives in the future. If all authorized shares beyond the current outstanding were issued, it would represent a potential dilution of over 300% for existing shareholders. Additionally, a new stock incentive plan was approved, reserving approximately 12.9 million shares for employee compensation, further contributing to potential future dilution. These approvals follow the recent FDA approval of UTEBZI, suggesting the company is preparing for potential financing activities to support commercialization and growth.